ARQ 501 in Combination With Docetaxel in Patients With Cancer
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety of ARQ 501 in combination with docetaxel
in patients with advanced or metastatic cancer. In addition, the study is designed to observe
the potential the combination of ARQ 501 and docetaxel have in treating cancer.
Phase:
Phase 1
Details
Lead Sponsor:
ArQule ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)